Review

Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China

Search for more papers by this author

Feng Zhang

Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China

Search for more papers by this author

Junbo Ge

*Author for correspondence: Tel.: +86 198 2141 3785;

E-mail Address: jbge@zs-hospital.sh.cn

Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, 200032, China

Search for more papers by this author

Published Online:16 Sep 2022https://doi.org/10.2217/fca-2022-0058

View article

Abstract

SGLT2 inhibitors have been developed as a novel class of glucose-lowering drugs affecting reabsorption of glucose and metabolic processes. They have been recently identified to be remarkably favorable in treating cardiovascular diseases, especially heart failure. Preclinical experiments have shown that SGLT2 inhibitors could hinder the progression of myocardial infarction and alleviate cardiac remodeling by mechanisms of metabolism influence, autophagy induction, inflammation attenuation and fibrosis reduction. Here we summarize the direct mechanism of SGLT2 inhibitors on myocardial infarction and investigate whether it could be applied to the clinic in improving cardiac function and healing after myocardial infarction.

Plain language summary

Inhibitors of the protein SGLT2, including empagliflozin and dapagliflozin, are some of the most efficient glucose-lowering drugs used for the treatment of diabetes. In recent years, researchers and clinicians have found that SGLT2 inhibitors could also be applied in the treatment of some cardiovascular diseases. Every year, a number of people, especially the elderly and disabled, experience the pain of myocardial infarction (‘heart attack’). Preclinical experiments have shown that SGLT2 inhibitors could hinder the progression of myocardial infarction. Some clinical trials have shown the same result. Hence, in the near future, SGLT2 inhibitors promise to be used as effective drugs in treating myocardial infarction.

Keywords:

Papers of special note have been highlighted as: • of interest

References

1. Roger VL. Epidemiology of heart failure. Circ. Res. 113(6), 646–659 (2013).
Medline CASGoogle Scholar
2. Lambert JM, Lopez EF, Lindsey ML. Macrophage roles following myocardial infarction. Int. J. Cardiol. 130(2), 147–158 (2008).
MedlineGoogle Scholar
3. Gorgojo-Martínez JJ. New glucose-lowering drugs for reducing cardiovascular risk in patients with type 2 diabetes mellitus. Hipertens. Riesgo Vasc. 36(3), 145–161 (2019).
Medline CASGoogle Scholar
4. Zelniker TA, Braunwald E. Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review. J. Am. Coll. Cardiol. 75(4), 422–434 (2020).
Medline CASGoogle Scholar
5. Santos-Gallego CG, Requena-Ibanez JA, San Antonio R et al. Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics. J. Am. Coll. Cardiol. 73(15), 1931–1944 (2019).
Medline CASGoogle Scholar
6. Lee TM, Chang NC, Lin SZ. Dapagliflozin, a selective SGLT2 inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic. Biol. Med. 104, 298–310 (2017).
Medline CASGoogle Scholar
7. Ahmed AS, Mona MM, Abdel-Kareem MA, Elsisy RA. SGLT2 inhibitor empagliflozin monotherapy alleviates renal oxidative stress in albino Wistar diabetic rats after myocardial infarction induction. Biomed. Pharmacother. 139, 111624 (2021).
Medline CASGoogle Scholar
8. Lim VG, Bell RM, Arjun S, Kolatsi-Joannou M, Long DA, Yellon DM. SGLT2 inhibitor, canagliflozin, attenuates myocardial infarction in the diabetic and nondiabetic heart. JACC Basic Transl. Sci. 4(1), 15–26 (2019). • SGLT2 inhibitors alleviate the death of cardiomyocytes in myocardial infarction.
MedlineGoogle Scholar
9. Yurista SR, Silljé HHW, Oberdorf-Maass SU et al. Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction. Eur. J. Heart Fail. 21(7), 862–873 (2019).
Medline CASGoogle Scholar
10. Kondo H, Akoumianakis I, Badi I et al. Effects of canagliflozin on human myocardial redox signalling: clinical implications. Eur. Heart J. 42(48), 4947–4960 (2021).
Medline CASGoogle Scholar
11. Onishi A, Fu Y, Patel R et al. A role for tubular Na+/H+ exchanger NHE3 in the natriuretic effect of the SGLT2 inhibitor empagliflozin. Am. J. Physiol.-Renal Physiol. 319(4), F712–F728 (2020).
Medline CASGoogle Scholar
12. Wallenius K, Kroon T, Hagstedt T et al. The SGLT2 inhibitor dapagliflozin promotes systemic FFA mobilization, enhances hepatic β-oxidation, and induces ketosis. J. Lipid Res.. 63(3), 100176 (2022).
Medline CASGoogle Scholar
13. Yu Y-W, Que J-Q, Liu S et al. Sodium-Glucose Co-transporter-2 Inhibitor of Dapagliflozin Attenuates Myocardial Ischemia/Reperfusion Injury by Limiting NLRP3 Inflammasome Activation and Modulating Autophagy. Front. Cardiovasc. Med. 8, 768214 (2022).
MedlineGoogle Scholar
14. Jiang K, Xu Y, Wang D et al. Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis. Protein Cell 13(5), 336–359 (2022). • Link between SGLT2 inhibitor and autophagy.
Medline CASGoogle Scholar
15. Uthman L, Nederlof R, Eerbeek O et al. Delayed ischaemic contracture onset by empagliflozin associates with NHE1 inhibition and is dependent on insulin in isolated mouse hearts. Cardiovasc. Res. 115(10), 1533–1545 (2019).
Medline CASGoogle Scholar
16. Nikolaou PE, Efentakis P, Abu Qourah F et al. Chronic empagliflozin treatment reduces myocardial infarct size in nondiabetic mice through STAT-3-mediated protection on microvascular endothelial cells and reduction of oxidative stress. Antioxid. Redox Signal. 34(7), 551–571 (2021).
Medline CASGoogle Scholar
17. Furtado RHM, Bonaca MP, Raz I et al. Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes mellitus and previous myocardial infarction. Circulation 139(22), 2516–2527 (2019).
Medline CASGoogle Scholar
18. Shimizu W, Kubota Y, Hoshika Y et al. Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial. Cardiovasc. Diabetol. 19(1), 148 (2020). • Clinical trials associated with SGLT2 inhibitors in myocardial infarction.
Medline CASGoogle Scholar
19. Paolisso P, Bergamaschi L, Santulli G et al. Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry. Cardiovasc. Diabetol. 21(1), 77 (2022).
Medline CASGoogle Scholar
20. Dambrova M, Zuurbier CJ, Borutaite V, Liepinsh E, Makrecka-Kuka M. Energy substrate metabolism and mitochondrial oxidative stress in cardiac ischemia/reperfusion injury. Free Radic Biol Med. 165,24–37 (2021).
Medline CASGoogle Scholar
21. Zuurbier CJ, Bertrand L, Beauloye CR et al. Cardiac metabolism as a driver and therapeutic target of myocardial infarction. J. Cell. Mol. Med. 24(11), 5937–5954 (2020).
Medline CASGoogle Scholar
22. Marton A, Kaneko T, Kovalik JP et al. Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation. Nat. Rev. Nephrol. 17(1), 65–77 (2021).
Medline CASGoogle Scholar
23. Inagaki N, Goda M, Yokota S, Maruyama N, Iijima H. Safety and efficacy of canagliflozin in Japanese patients with type 2 diabetes mellitus: post hoc subgroup analyses according to body mass index in a 52-week open-label study. Expert Opin. Pharmacother. 16(11), 1577–1591 (2015).
Medline CASGoogle Scholar
24. Lommi J, Kupari M, Koskinen P et al. Blood ketone bodies in congestive heart failure. J. Am. Coll. Cardiol. 28(3), 665–672 (1996).
Medline CASGoogle Scholar
25. Ferrannini E, Baldi S, Frascerra S et al. Shift to fatty substrate utilization in response to sodium–glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes 65(5), 1190–1195 (2016).
Medline CASGoogle Scholar
26. Yurista SR, Chong CR, Badimon JJ, Kelly DP, De Boer RA, Westenbrink BD. Therapeutic potential of ketone bodies for patients with cardiovascular disease: JACC state-of-the-art review. J. Am. Coll. Cardiol. 77(13), 1660–1669 (2021).
Medline CASGoogle Scholar
27. Lindsay RT, Dieckmann S, Krzyzanska D et al. β-hydroxybutyrate accumulates in the rat heart during low-flow ischaemia with implications for functional recovery. ELife 10, e71270 (2021).
Medline CASGoogle Scholar
28. Ferrannini E, Mark M, Mayoux E. CV Protection in the EMPA-REG OUTCOME trial: a ‘thrifty substrate’ hypothesis. Diabetes Care 39(7), 1108–1114 (2016).
MedlineGoogle Scholar
29. Kolb H, Kempf K, Röhling M, Lenzen-Schulte M, Schloot NC, Martin S. Ketone bodies: from enemy to friend and guardian angel. BMC Med. 19(1), 313 (2021).
Medline CASGoogle Scholar
30. Halestrap AP. The SLC16 gene family – structure, role and regulation in health and disease. Mol. Aspects Med. 34(2–3), 337–349 (2013).
Medline CASGoogle Scholar
31. Puchalska P, Crawford PA. Multi-dimensional roles of ketone bodies in fuel metabolism, signaling, and therapeutics. Cell Metab. 25(2), 262–284 (2017). • The role of ketone bodies in cardiovascular diseases.
Medline CASGoogle Scholar
32. Uchihashi M, Hoshino A, Okawa Y et al. Cardiac-specific Bdh1 overexpression ameliorates oxidative stress and cardiac remodeling in pressure overload-induced heart failure. Circ. Heart Fail. 10(12), e004417 (2017).
Medline CASGoogle Scholar
33. Song Y, Huang C, Sin et al. Attenuation of adverse postinfarction left ventricular remodeling with empagliflozin enhances mitochondria-linked cellular energetics and mitochondrial biogenesis. Int. J. Mol. Sci. 23(1), 437 (2021).
MedlineGoogle Scholar
34. Mizuno M, Kuno A, Yano T et al. Empagliflozin normalizes the size and number of mitochondria and prevents reduction in mitochondrial size after myocardial infarction in diabetic hearts. Physiol. Rep. 6(12), e13741 (2018).
MedlineGoogle Scholar
35. Moellmann J, Klinkhammer BM, Droste P et al. Empagliflozin improves left ventricular diastolic function of db/db mice. Biochim. Biophys. Acta Mol. Basis Dis. 1866(8), 165807 (2020).
Medline CASGoogle Scholar
36. Baker HE, Kiel AM, Luebbe ST et al. Inhibition of sodium–glucose cotransporter-2 preserves cardiac function during regional myocardial ischemia independent of alterations in myocardial substrate utilization. Basic Res. Cardiol. 114(3), 25 (2019).
MedlineGoogle Scholar
37. Abdurrachim D, Teo XQ, Woo CC et al. Empagliflozin reduces myocardial ketone utilization while preserving glucose utilization in diabetic hypertensive heart disease: a hyperpolarized ¹³C magnetic resonance spectroscopy study. Diabetes Obes. Metab. 21(2), 357–365 (2019).
Medline CASGoogle Scholar
38. Lopaschuk GD, Verma S. Empagliflozin’s fuel hypothesis: not so soon. Cell Metab. 24(2), 200–202 (2016).
Medline CASGoogle Scholar
39. Zhang H, Uthman L, Bakker D et al. Empagliflozin decreases lactate generation in an NHE-1 dependent fashion and increases α-ketoglutarate synthesis from palmitate in type II diabetic mouse hearts. Front. Cardiovasc. Med. 7, 592233 (2020). • SGLT2 inhibitors affect the metabolism of the heart.
Medline CASGoogle Scholar
40. Kuang M, Febbraio M, Wagg C, Lopaschuk GD, Dyck JR. Fatty acid translocase/CD36 deficiency does not energetically or functionally compromise hearts before or after ischemia. Circulation 109(12), 1550–1557 (2004).
Medline CASGoogle Scholar
41. Dyck JR, Lopaschuk GD. Malonyl CoA control of fatty acid oxidation in the ischemic heart. J. Mol. Cell. Cardiol. 34(9), 1099–1109 (2002).
Medline CASGoogle Scholar
42. Schlaepfer IR, Joshi M. CPT1A-mediated fat oxidation, mechanisms, and therapeutic potential. Endocrinology 161(2), bqz046 (2020).
MedlineGoogle Scholar
43. Basu D, Huggins LA, Scerbo D et al. Mechanism of increased LDL (low-density lipoprotein) and decreased triglycerides with SGLT2 (sodium–glucose cotransporter 2) inhibition. Arterioscler. Thromb. Vasc. Biol. 38(9), 2207–2216 (2018).
Medline CASGoogle Scholar
44. Mcgarry JD, Brown NF. The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. Eur. J. Biochem. 244(1), 1–14 (1997).
Medline CASGoogle Scholar
45. Mcgarry JD, Takabayashi Y, Foster DW. The role of malonyl-CoA in the coordination of fatty acid synthesis and oxidation in isolated rat hepatocytes. J. Biol. Chem. 253(22), 8294–8300 (1978).
Medline CASGoogle Scholar
46. Awan MM, Saggerson ED. Malonyl-CoA metabolism in cardiac myocytes and its relevance to the control of fatty acid oxidation. Biochem. J. 295 (Pt 1), 61–66 (1993).
Medline CASGoogle Scholar
47. Li L, Li Q, Huang W et al. Dapagliflozin alleviates hepatic steatosis by restoring autophagy via the AMPK-mTOR pathway. Front. Pharmacol. 12, 589273 (2021).
Medline CASGoogle Scholar
48. Trang NN, Chung CC, Lee TW et al. Empagliflozin and liraglutide differentially modulate cardiac metabolism in diabetic cardiomyopathy in rats. Int. J. Mol. Sci. 22(3), 1177 (2021).
Medline CASGoogle Scholar
49. Pepino MY, Kuda O, Samovski D, Abumrad NA. Structure-function of CD36 and importance of fatty acid signal transduction in fat metabolism. Annu Rev Nutr. 34,281–303 (2014).
Medline CASGoogle Scholar
50. Goodwin GW, Taegtmeyer H. Regulation of fatty acid oxidation of the heart by MCD and ACC during contractile stimulation. Am J Physiol. 277(4), E772–E777 (1999).
Medline CASGoogle Scholar
51. Maréchal L, Laviolette M, Rodrigue-Way A et al. The CD36-PPARγ pathway in metabolic disorders. Int J Mol Sci. 19(5), 1529 (2018).
Google Scholar
52. Puigserver P, Spiegelman BM. Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. Endocr. Rev. 24(1), 78–90 (2003).
Medline CASGoogle Scholar
53. Finck BN, Lehman JJ, Leone TC et al. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J. Clin. Invest. 109(1), 121–130 (2002).
Medline CASGoogle Scholar
54. Shao Q, Meng L, Lee S et al. Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats. Cardiovasc. Diabetol. 18(1), 165 (2019).
Medline CASGoogle Scholar
55. Wei D, Liao L, Wang H, Zhang W, Wang T, Xu Z. Canagliflozin ameliorates obesity by improving mitochondrial function and fatty acid oxidation via PPARα in vivo and in vitro. Life Sci. 247, 117414 (2020).
Medline CASGoogle Scholar
56. Neinast MD, Jang C, Hui S et al. Quantitative analysis of the whole-body metabolic fate of branched-chain amino acids. Cell Metab. 29(2), 417–429.e414 (2019).
Medline CASGoogle Scholar
57. Sag CM, Wagner S, Maier LS. Role of oxidants on calcium and sodium movement in healthy and diseased cardiac myocytes. Free Radic. Biol. Med. 63, 338–349 (2013).
Medline CASGoogle Scholar
58. Uthman L, Baartscheer A, Bleijlevens B et al. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na⁺/H⁺ exchanger, lowering of cytosolic Na⁺ and vasodilation. Diabetologia 61(3), 722–726 (2018).
Medline CASGoogle Scholar
59. Baartscheer A, Schumacher CA, Wüst RC et al. Empagliflozin decreases myocardial cytoplasmic Na⁺ through inhibition of the cardiac Na⁺/H⁺ exchanger in rats and rabbits. Diabetologia 60(3), 568–573 (2017).
Medline CASGoogle Scholar
60. Philippaert K, Kalyaanamoorthy S, Fatehi M et al. Cardiac late sodium channel current is a molecular target for the sodium/glucose cotransporter 2 inhibitor empagliflozin. Circulation 143(22), 2188–2204 (2021).
Medline CASGoogle Scholar
61. Packer M. Autophagy stimulation and intracellular sodium reduction as mediators of the cardioprotective effect of sodium-glucose cotransporter 2 inhibitors. Eur J. Heart Fail. 22(4), 618–628 (2020).
Medline CASGoogle Scholar
62. Zhai P, Galeotti J, Liu et al. An angiotensin II type 1 receptor mutant lacking epidermal growth factor receptor transactivation does not induce angiotensin II-mediated cardiac hypertrophy. Circ. Res. 99(5), 528–536 (2006).
Medline CASGoogle Scholar
63. Goldberg MA, Dunning SP, Bunn HF. Regulation of the erythropoietin gene: evidence that the oxygen sensor is a heme protein. Science 242(4884), 1412–1415 (1988).
Medline CASGoogle Scholar
64. Camberos-Luna L, Gerónimo-Olvera C, Montiel T, Rincon-Heredia R, Massieu L. The ketone body, β-hydroxybutyrate stimulates the autophagic flux and prevents neuronal death induced by glucose deprivation in cortical cultured neurons. Neurochem. Res. 41(3), 600–609 (2016).
Medline CASGoogle Scholar
65. Sayour AA, Korkmaz-Icöz S, Loganathan S et al. Acute canagliflozin treatment protects against in vivo myocardial ischemia–reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation. J. Transl. Med. 17(1), 127 (2019).
MedlineGoogle Scholar
66. Hawley SA, Ford RJ, Smith BK et al. The Na+/glucose cotransporter inhibitor canagliflozin activates AMPK by inhibiting mitochondrial function and increasing cellular AMP levels. Diabetes 65(9), 2784–2794 (2016).
Medline CASGoogle Scholar
67. Umino H, Hasegawa K, Minakuchi H et al. High basolateral glucose increases sodium-glucose cotransporter 2 and reduces sirtuin-1 in renal tubules through glucose transporter-2 detection. Sci. Rep. 8(1), 6791 (2018).
MedlineGoogle Scholar
68. Kim S, Jo CH, Kim GH. Effects of empagliflozin on nondiabetic salt-sensitive hypertension in uninephrectomized rats. Hypertens. Res. 42(12), 1905–1915 (2019).
Medline CASGoogle Scholar
69. Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat. Rev. Mol. Cell Biol. 13(4), 251–262 (2012).
Medline CASGoogle Scholar
70. Pillai VB, Sundaresan NR, Gupta MP. Regulation of Akt signaling by sirtuins: its implication in cardiac hypertrophy and aging. Circ. Res. 114(2), 368–378 (2014).
Medline CASGoogle Scholar
71. Wang L, Quan N, Sun W et al. Cardiomyocyte-specific deletion of Sirt1 gene sensitizes myocardium to ischaemia and reperfusion injury. Cardiovasc. Res. 114(6), 805–821 (2018).
Medline CASGoogle Scholar
72. Luo G, Jian Z, Zhu Y et al. Sirt1 promotes autophagy and inhibits apoptosis to protect cardiomyocytes from hypoxic stress. Int. J. Mol. Med. 43(5), 2033–2043 (2019).
Medline CASGoogle Scholar
73. Semenza GL. Regulation of metabolism by hypoxia-inducible factor 1. Cold Spring Harb. Symp. Quant. Biol. 76, 347–353 (2011).
Medline CASGoogle Scholar
74. Kim JW, Lee YJ, You YH et al. Effect of sodium–glucose cotransporter 2 inhibitor, empagliflozin, and α-glucosidase inhibitor, voglibose, on hepatic steatosis in an animal model of type 2 diabetes. J. Cell. Biochem. doi:10.1002/jcb.28141 (.2018) (Epub ahead of print).
Google Scholar
75. Lv B, Hua T, Li F et al. Hypoxia-inducible factor 1 α protects mesenchymal stem cells against oxygen-glucose deprivation-induced injury via autophagy induction and PI3K/AKT/mTOR signaling pathway. Am. J. Transl. Res. 9(5), 2492–2499 (2017).
Medline CASGoogle Scholar
76. Lee YH, Kim SH, Kang JM et al. Empagliflozin attenuates diabetic tubulopathy by improving mitochondrial fragmentation and autophagy. Am. J. Physiol. Renal Physiol. 317(4), F767–f780 (2019).
Medline CASGoogle Scholar
77. Korbut AI, Taskaeva IS, Bgatova NP et al. SGLT2 inhibitor empagliflozin and DPP4 inhibitor linagliptin reactivate glomerular autophagy in db/db mice, a model of type 2 diabetes. Int. J. Mol. Sci. 21(8), 2987 (2020).
CASGoogle Scholar
78. Ren C, Sun K, Zhang Y et al. Sodium–glucose cotransporter-2 inhibitor empagliflozin ameliorates sunitinib-induced cardiac dysfunction via regulation of AMPK-mTOR signaling pathway-mediated autophagy. Front. Pharmacol. 12, 664181 (2021).
Medline CASGoogle Scholar
79. Yu YW, Que JQ, Liu S et al. Sodium–glucose co-transporter-2 inhibitor of dapagliflozin attenuates myocardial ischemia/reperfusion injury by limiting NLRP3 inflammasome activation and modulating autophagy. Front. Cardiovasc. Med. 8, 768214 (2021).
Medline CASGoogle Scholar
80. Xu C, Wang W, Zhong J et al. Canagliflozin exerts anti-inflammatory effects by inhibiting intracellular glucose metabolism and promoting autophagy in immune cells. Biochem. Pharmacol. 152, 45–59 (2018).
Medline CASGoogle Scholar
81. Liu Y, Wu M, Xu J, Xu B, Kang L. Empagliflozin prevents from early cardiac injury post myocardial infarction in non-diabetic mice. Eur J. Pharm. Sci. 161, 105788 (2021).
Medline CASGoogle Scholar
82. Lee H, Yoon Y. Mitochondrial fission and fusion. Biochem. Soc. Trans. 44(6), 1725–1735 (2016).
Medline CASGoogle Scholar
83. Dorn GW 2nd, Vega RB, Kelly DP. Mitochondrial biogenesis and dynamics in the developing and diseased heart. Genes Dev. 29(19), 1981–1991 (2015).
Medline CASGoogle Scholar
84. Takagi S, Li J, Takagaki Y et al. Ipragliflozin improves mitochondrial abnormalities in renal tubules induced by a high-fat diet. J. Diabetes Investig. 9(5), 1025–1032 (2018).
Medline CASGoogle Scholar
85. Wang CC, Li Y, Qian XQ et al. Empagliflozin alleviates myocardial I/R injury and cardiomyocyte apoptosis via inhibiting ER stress-induced autophagy and the PERK/ATF4/Beclin1 pathway. J. Drug Target. 30(8), 858–872 (2022).
Medline CASGoogle Scholar
86. Berry DL, Baehrecke EH. Growth arrest and autophagy are required for salivary gland cell degradation in Drosophila. Cell 131(6), 1137–1148 (2007).
Medline CASGoogle Scholar
87. Mariño G, Niso-Santano M, Baehrecke EH, Kroemer G. Self-consumption: the interplay of autophagy and apoptosis. Nat. Rev. Mol. Cell Biol. 15(2), 81–94 (2014).
Medline CASGoogle Scholar
88. Xu J, Kitada M, Ogura Y, Liu H, Koya D. Dapagliflozin restores impaired autophagy and suppresses inflammation in high glucose-treated HK-2 cells. Cells 10(6), 1457 (2021).
Medline CASGoogle Scholar
89. Wang CY, Chen CC, Lin MH et al. TLR9 binding to beclin 1 and mitochondrial SIRT3 by a sodium–glucose co-transporter 2 inhibitor protects the heart from doxorubicin toxicity. Biology (Basel) 9(11), 369 (2020). • SGLT2 inhibitors enhance autophagic flux.
CASGoogle Scholar
90. Han JH, Oh TJ, Lee G et al. The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE (-/-) mice fed a western diet. Diabetologia 60(2), 364–376 (2017).
Medline CASGoogle Scholar
91. Koyani CN, Plastira I, Sourij H et al. Empagliflozin protects heart from inflammation and energy depletion via AMPK activation. Pharmacol. Res. 158, 104870 (2020).
Medline CASGoogle Scholar
92. Abdollahi E, Keyhanfar F, Delbandi AA, Falak R, Hajimiresmaiel SJ, Shafiei M. Dapagliflozin exerts anti-inflammatory effects via inhibition of LPS-induced TLR-4 overexpression and NF-κB activation in human endothelial cells and differentiated macrophages. Eur. J. Pharmacol. 918, 174715 (2022).
Medline CASGoogle Scholar
93. Toldo S, Mezzaroma E, Mauro AG, Salloum F, Van Tassell BW, Abbate A. The inflammasome in myocardial injury and cardiac remodeling. Antioxid. Redox Signal. 22(13), 1146–1161 (2015).
Medline CASGoogle Scholar
94. Mezzaroma E, Toldo S, Farkas D et al. The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse. Proc. Natl Acad. Sci. USA 108(49), 19725–19730 (2011).
Medline CASGoogle Scholar
95. Toldo S, Abbate A. The NLRP3 inflammasome in acute myocardial infarction. Nat. Rev. Cardiol. 15(4), 203–214 (2018).
Medline CASGoogle Scholar
96. Sun Q, Fan J, Billiar TR, Scott MJ. Inflammasome and autophagy regulation – a two-way street. Mol. Med. 23, 188–195 (2017).
Medline CASGoogle Scholar
97. Leng W, Wu M, Pan H et al. The SGLT2 inhibitor dapagliflozin attenuates the activity of ROS–NLRP3 inflammasome axis in steatohepatitis with diabetes mellitus. Ann. Transl. Med. 7(18), 429 (2019). • SGLT2 inhibitors influence the formation of NLRP3 inflammasome.
Medline CASGoogle Scholar
98. Sukhanov S, Higashi Y, Yoshida T et al. The SGLT2 inhibitor empagliflozin attenuates interleukin-17A-induced human aortic smooth muscle cell proliferation and migration by targeting TRAF3IP2/ROS/NLRP3/caspase-1-dependent IL-1β and IL-18 secretion. Cell. Signal. 77, 109825 (2021).
Medline CASGoogle Scholar
99. Kim SR, Lee SG, Kim SH et al. SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nat. Commun. 11(1), 2127 (2020).
Medline CASGoogle Scholar
100. Ye Y, Bajaj M, Yang HC, Perez-Polo JR, Birnbaum Y. SGLT-2 inhibition with dapagliflozin reduces the activation of the NLRP3/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. Further augmentation of the effects with saxagliptin, a DPP4 inhibitor. Cardiovasc. Drugs Ther. 31(2), 119–132 (2017).
MedlineGoogle Scholar
101. Li C, Zhang J, Xue M et al. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc. Diabetol. 18(1), 15 (2019).
MedlineGoogle Scholar
102. Youm YH, Nguyen KY, Grant RW et al. The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat. Med. 21(3), 263–269 (2015).
Medline CASGoogle Scholar
103. Quagliariello V, De Laurentiis M, Rea D et al. The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin. Cardiovasc. Diabetol. 20(1), 150 (2021). • SGLT2 inhibitors play a anti-inflammatory role in cardiovascular diseases.
Medline CASGoogle Scholar
104. Lee N, Heo YJ, Choi SE et al. Anti-inflammatory effects of empagliflozin and gemigliptin on LPS-stimulated macrophage via the IKK/NF-κB, MKK7/JNK, and JAK2/STAT1 signalling pathways. J. Immunol. Res. 2021, 9944880 (2021).
MedlineGoogle Scholar
105. Matsuzawa-Ishimoto Y, Hwang S, Cadwell K. Autophagy and inflammation. Annu. Rev. Immunol. 36, 73–101 (2018).
Medline CASGoogle Scholar
106. Gordon S, Plüddemann A. Tissue macrophages: heterogeneity and functions. BMC Biol. 15(1), 53 (2017).
MedlineGoogle Scholar
107. Shapouri-Moghaddam A, Mohammadian S, Vazini H et al. Macrophage plasticity, polarization, and function in health and disease. J. Cell. Physiol. 233(9), 6425–6440 (2018).
Medline CASGoogle Scholar
108. Xu L, Nagata N, Nagashimada M et al. SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice. EBioMedicine 20, 137–149 (2017).
MedlineGoogle Scholar
109. Vats D, Mukundan L, Odegaard JI et al. Oxidative metabolism and PGC-1beta attenuate macrophage-mediated inflammation. Cell Metab. 4(1), 13–24 (2006).
Medline CASGoogle Scholar
110. Jha AK, Huang SC, Sergushichev A et al. Network integration of parallel metabolic and transcriptional data reveals metabolic modules that regulate macrophage polarization. Immunity 42(3), 419–430 (2015).
Medline CASGoogle Scholar
111. Ugusman A, Kumar J, Aminuddin A. Endothelial function and dysfunction: impact of sodium–glucose cotransporter 2 inhibitors. Pharmacol. Ther. 224, 107832 (2021).
Medline CASGoogle Scholar
112. Park SH, Farooq MA, Gaertner S et al. Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat. Cardiovasc. Diabetol. 19(1), 19 (2020).
Medline CASGoogle Scholar
113. Correale M, Mazzeo P, Mallardi A et al. Switch to SGLT2 inhibitors and improved endothelial function in diabetic patients with chronic heart failure. Cardiovasc. Drugs Ther. doi:10.1007/s10557-021-07254-3 (2021) (Epub ahead of print).
Google Scholar
114. Li H, Shin SE, Seo MS et al. The anti-diabetic drug dapagliflozin induces vasodilation via activation of PKG and Kv channels. Life Sci. 197, 46–55 (2018).
Medline CASGoogle Scholar
115. Zainordin NA, Hatta S, Mohamed Shah FZ et al. Effects of dapagliflozin on endothelial dysfunction in type 2 diabetes with established ischemic heart disease (EDIFIED). J. Endocr. Soc. 4(1), bvz017 (2020).
MedlineGoogle Scholar
116. Fuentes E, Moore-Carrasco R, De Andrade Paes AM, Trostchansky A. Role of platelet activation and oxidative stress in the evolution of myocardial infarction. J. Cardiovasc. Pharmacol. Ther. 24(6), 509–520 (2019).
Medline CASGoogle Scholar
117. Khemais-Benkhiat S, Belcastro E, Idris-Khodja N et al. Angiotensin II-induced redox-sensitive SGLT1 and 2 expression promotes high glucose-induced endothelial cell senescence. J. Cell. Mol. Med. 24(3), 2109–2122 (2020).
Medline CASGoogle Scholar
118. Gaspari T, Spizzo I, Liu H et al. Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: a potential mechanism for inhibition of atherogenesis. Diab. Vasc. Dis. Res. 15(1), 64–73 (2018).
Medline CASGoogle Scholar
119. Uthman L, Li X, Baartscheer A et al. Empagliflozin reduces oxidative stress through inhibition of the novel inflammation/NHE/[Na⁺]_c/ROS-pathway in human endothelial cells. Biomed. Pharmacother. 146, 112515 (2022).
Medline CASGoogle Scholar
120. Kolijn D, Pabel S, Tian Y et al. Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory–oxidative pathways and protein kinase Gα oxidation. Cardiovasc. Res. 117(2), 495–507 (2021).
Medline CASGoogle Scholar
121. Turner NA, Porter KE. Function and fate of myofibroblasts after myocardial infarction. Fibrogenesis Tissue Repair 6(1), 5 (2013).
Medline CASGoogle Scholar
122. Frangogiannis NG. The extracellular matrix in myocardial injury, repair, and remodeling. J. Clin. Invest. 127(5), 1600–1612 (2017).
MedlineGoogle Scholar
123. Li G, Zhao C, Fang S. SGLT2 promotes cardiac fibrosis following myocardial infarction and is regulated by miR-141. Exp. Ther. Med. 22(1), 715 (2021).
MedlineGoogle Scholar
124. Goerg J, Sommerfeld M, Greiner B et al. Low-dose empagliflozin improves systolic heart function after myocardial infarction in rats: regulation of MMP9, NHE1, and SERCA2a. Int. J. Mol. Sci. 22(11), 5437 (2021).
Medline CASGoogle Scholar

Vol. 18, No. 11

Metrics

Downloaded 379 times

History

Received 21 June 2022

Accepted 31 August 2022

Published online 16 September 2022

Published in print November 2022

Information

Keywords

Author contributions

J Zhang, F Zhang and J Ge contributed to the completion of the review. J Zhang mainly finished the draft. J Ge and F Zhang provided some modifying suggestions to polish the work. All authors have approved the final manuscript submission.

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

PDF download

SGLT2 inhibitors protect cardiomyocytes from myocardial infarction: a direct mechanism?

Abstract

Plain language summary

References